PGI2as a Regulator of Inflammatory Diseases
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Prostacyclin, or PGI 2, is an end product derived from the sequential metabolism of arachidonic acid via cyclooxygenase and PGI synthase (PGIS). The receptor for PGI 2, IP, can be found on a variety of cell types and signaling through this receptor exhibits broad physiological effects. Historically, PGI 2 has been understood to play a role in cardiovascular health, specifically having powerful vasodilatory effects via relaxation of smooth muscle and inhibiting of platelet aggregation. For these reasons, PGI 2 has a long history of use for the treatment of pulmonary arterial hypertension (PAH). Only recently, its importance as an immunomodulatory agent has been investigated. PGI 2 regulates both the innate and adaptive immune systems and its effects are, for the most part, thought to be anti-inflammatory or immunosuppressive in nature, which may have implications for its further clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Needleman, P., Moncada, S., Bunting, S., Vane, J. R., Hamberg, M., & Samuelsson, B. (1976) · Nature · doi:10.1038/261558a0 · Cited by 526 · cited 1×
“Prostacyclin, or PGI2, was first reported by Needleman and Vane in 1976 and is an end product derived from the sequential metabolism of arachidonic acid via cyclooxygenase2 (COX-2) and prostacyclin synthase (PGIS) [1].”
BackgroundCOX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice
Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M., & FitzGerald, G. A. (2004) · Science · doi:10.1126/science.1103333 · Cited by 431
Dahlén, S. E., Hansson, G., Hedqvist, P., Björck, T., Granström, E., & Dahlén, B. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.6.1712 · Cited by 415
Zou, M., Martin, C., & Ullrich, V. (1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.7.707 · Cited by 289 · cited 1×
“Production of PGI2 is decreased by the inhibition of PGIS by tyrosine-nitrating agents such as peroxynitrite [11] and tetranitromethane [12].”
BackgroundZou, M.-H., & Ullrich, V. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00160-3 · Cited by 231 · cited 1×
“Production of PGI2 is decreased by the inhibition of PGIS by tyrosine-nitrating agents such as peroxynitrite [11] and tetranitromethane [12].”
BackgroundHonda, T., Segi-Nishida, E., Miyachi, Y., & Narumiya, S. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051310 · Cited by 208
Zhou, W., Hashimoto, K., Goleniewska, K., O’Neal, J. F., Ji, S., Blackwell, T. S., FitzGerald, G. A., Egan, K. M., Geraci, M. W., & Peebles, R. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.702 · Cited by 165
Self-citationSchulman, E. S., Newball, H. H., Demers, L. M., Fitzpatrick, F. A., & Adkinson, N. F. (1981) · PubMed · doi:10.1164/arrd.1981.124.4.402 · Cited by 163
Prostacyclin Prevents Pulmonary Endothelial Cell Apoptosis Induced by Cigarette Smoke
Nana-Sinkam, S. P., Lee, J. D., Sotto-Santiago, S. M., Stearman, R. S., Keith, R. L., Choudhury, Q. G., Cool, C. D., Parr, J. E., Moore, M. D., Bull, T. M., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-724oc · Cited by 140 · cited 12×
“PGI2 has a long history of use for the treatment of pulmonary arterial hypertension (PAH) [14, 16, 28].”
BackgroundInfluentialProstacyclin: A Vascular Mediator
Vane, J. R., & Corin, R. E. (2003) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(03)00385-x · Cited by 138 · cited 1×
“It is hypothesized that early depletion of PGI2 from endothelial tissue could lead to the pathogenesis of atherosclerosis by causing deposition of adipocyte lipid in smooth muscle cells [26].”
BackgroundKing, V. L., Trivedi, D. B., Gitlin, J. M., & Loftin, C. D. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000216119.79008.ac · Cited by 137 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2012, Article ID 926968, 9 pages doi:10.1155/2012/926968”
BackgroundInfluentialAugmentation of allergic inflammation in prostanoid IP receptor deficient mice
Takahashi, Y., Tokuoka, S., Masuda, T., Hirano, Y., Nagao, M., Tanaka, H., Inagaki, N., Narumiya, S., & Nagai, H. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704872 · Cited by 132 · cited 2×
“In an acute model of allergic inflammation induced by ovalbumin (OVA), IP-deficient mice had significantly greater airway inflammatory responses consisting of increased plasma extravasation, leukocyte accumulation, and both IL4 and IL-5 production in the airways after sensitization and exposure to inhaled antigen [20].”
BackgroundPulichino, A.-M., Rowland, S., Wu, T. Y.-H., Clark, P., Xu, D., Mathieu, M., Riendeau, D., & Audoly, L. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110387 · Cited by 131 · cited 5×
“Similarly, in an IP-deficient mouse model of collagenantibody induced chronic inflammatory arthritis, the reduction in arthritis scores was 91% compared to a wild-type control group [33].”
BackgroundMethodInfluentialCOX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis
Lovgren, A. K., Jania, L. A., Hartney, J. M., Parsons, K. K., Audoly, L. P., FitzGerald, G. A., Tilley, S. L., & Koller, B. H. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00492.2005 · Cited by 128 · cited 3×
“IP receptors are also found on many cell types in the lung such as macrophages, pneumocytes, smooth muscle cells, and fibroblasts [17].”
BackgroundIdzko, M., Hammad, H., van Nimwegen, M., Kool, M., Vos, N., Hoogsteden, H. C., & Lambrecht, B. N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28949 · Cited by 124 · cited 2×
“Lastly, in a mouse model of asthma, inhaled iloprost, a PGI2 analogue, decreased the cardinal features of asthma such as Th2 cytokine production, eosinophilic airway inflammation, goblet cell hyperplasia, and bronchial airway hyperresponsiveness [24].”
BackgroundRole of Prostaglandin I2 in Airway Remodeling Induced by Repeated Allergen Challenge in Mice
Nagao, K., Tanaka, H., Komai, M., Masuda, T., Narumiya, S., & Nagai, H. (2003) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2003-0035oc · Cited by 99 · cited 2×
“PGI2 analogues play a key role via inhibition of Th1 and Th2 cytokine production from CD4 T cells [21, 42] although the specifics remain controversial as we will see in the discussion below.”
BackgroundProstaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells
Zhou, W., Blackwell, T. S., Goleniewska, K., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0606375 · Cited by 91 · cited 2×
“In a mouse study using PGI2 analogues, cicaprost and iloprost, IFN-γ from Th1 cells and IL-4, L-10, and IL13 from Th2 cells were diminished in a dose dependent manner [41].”
BackgroundAronoff, D. M., Peres, C. M., Serezani, C. H., Ballinger, M. N., Carstens, J. K., Coleman, N., Moore, B. B., Peebles, R. S., Faccioli, L. H., & Peters-Golden, M. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1628 · Cited by 90 · cited 2×
“Using a well characterized FcRmediated model of phagocytosis, activation of the IP receptor inhibited phagocytosis of IgG-opsonized targets in peritoneal macrophages to a much greater extent compared to alveolar macrophages [35].”
BackgroundSelf-citationJaffar, Z. H., Ferrini, M. E., Buford, M. C., FitzGerald, G. A., & Roberts, K. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.9.6193 · Cited by 80 · cited 2×
“10 Th2 cells pretreated with PGI2, there was significantly decreased pulmonary inflammation and airway hyperreactivity [22].”
BackgroundA prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice
Zhu, Y.-J., Liu, Y., Zhou, W., Xiang, R., Jiang, L., Huang, K., Xiao, Y. P., Guo, Z., & Gao, J. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-34 · Cited by 78
Jaffar, Z. H., Wan, K.-S., & Roberts, K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5997 · Cited by 74 · cited 3×
“COX-2 inhibition and the prevention of PGI2 formation was associated with increased bronchial airway hyperresponsiveness, elevated lung expression of Th2 cytokines, and decreased IL-10 production [4].”
BackgroundNakajima, S., Honda, T., Sakata, D., Egawa, G., Tanizaki, H., Otsuka, A., Moniaga, C. S., Watanabe, T., Miyachi, Y., Narumiya, S., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903260 · Cited by 68 · cited 2×
“In IP-deficient mice subjected to a chronic contact hypersensitivity model showed a significantly decreased contact hypersensitivity response [44].”
BackgroundMurakami, S., Nagaya, N., Itoh, T., Kataoka, M., Iwase, T., Horio, T., Miyahara, Y., Sakai, Y., Kangawa, K., & Kimura, H. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00042.2005 · Cited by 67 · cited 1×
“It has both PGI2 activity and thromboxane synthase inhibitory activity [47].”
BackgroundTargeted Deletions of Cyclooxygenase-2 and Atherogenesis in Mice
Hui, Y., Ricciotti, E., Crichton, I., Zhou, Y., Wang, D., Stubbe, J., Wang, M., Puré, E., & FitzGerald, G. A. (2010) · Circulation · doi:10.1161/circulationaha.109.910687 · Cited by 65 · cited 1×
“Hindawi Publishing Corporation Mediators of Inflammation Volume 2012, Article ID 926968, 9 pages doi:10.1155/2012/926968”
BackgroundInfluentialYin, H., Cheng, L., Langenbach, R. J., & Ju, C. (2006) · Hepatology · doi:10.1002/hep.21493 · Cited by 59 · cited 3×
“The protection provided by beraprost is postulated to stem from the maintenance of hepatic blood flow via beraprost’s vasodilatory effects [7].”
BackgroundInfluentialCamacho, M., Rodríguez, C., Guadall, A., Alcolea, S., Orriols, M., Escudero, J.-R., Martínez‐González, J., & Vila, L. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011007 · Cited by 48 · cited 2×
“Blocking PGI2 via COX-2 inhibition resulted in a marked increase in Th2 mediated lung inflammation in response to OVA challenge.”
BackgroundInfluentialProstacyclin in the intensive care setting
Ivy, D. D. (2010) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0b013e3181d10845 · Cited by 45 · cited 15×
“Inhaled iloprost can cause the development of reactive airway obstruction therefore limiting its use [46].”
BackgroundMethodInfluentialHashimoto, K., Graham, B. S., Geraci, M. W., FitzGerald, G. A., Egan, K. M., Zhou, W., Goleniewska, K., O’Neal, J. F., Morrow, J. D., Durbin, R. K., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10303-10309.2004 · Cited by 44 · cited 2×
“In contrast, IPdeficient mice had longer more severe illness with prolonged viral replication [31].”
BackgroundSelf-citationLehmann, C., König, J.-P., Dettmann, J., Birnbaum, J., & Kox, W. J. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00019 · Cited by 36 · cited 1×
“Iloprost attenuated leukocyte adherence in both postcapillary and collecting intestinal venules and improved intestinal microvascular blood flow without affecting mean arterial pressure or heart rate [27].”
BackgroundStrassheim, D., Riddle, S. R., Burke, D. L., Geraci, M. W., & Stenmark, K. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901045 · Cited by 35 · cited 2×
“Iloprost reduced IFN-γ and IL-6 induced MCP-1, IL-8, RANTES, and TNFα production in human monocytes [40].”
BackgroundWade, M. L., Voelkel, N. F., & Fitzpatrick, F. A. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1417 · Cited by 33 · cited 1×
“Lastly, PGIS can be limited by substrate-dependent suicide inactivation if there is adequate conversion of PGH2, the substrate for PGIS, which causes accumulation of inactivated enzyme [13].”
BackgroundIloprost has potent anti‐inflammatory properties on human monocyte‐derived dendritic cells
Müller, T., Dürk, T., Blumenthal, B., Herouy, Y., Sorichter, S., Grimm, M., Panther, E., Cicko, S., Norgauer, J., & Idzko, M. (2010) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2010.03558.x · Cited by 33 · cited 4×
“PGI2 analogues also increased production of anti-inflammatory IL-10 and diminished chemokine production in mice suggesting an overall anti-inflammatory effect [42].”
BackgroundInfluentialRetinoic acid induces PGI synthase expression in human endothelial cells
Camacho, M., Rodríguez, C., Salazar, J., Martínez‐González, J., Ribalta, J., Escudero, J.-R., Masana, L., & Vila, L. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m700559-jlr200 · Cited by 32
Prostacyclin signaling regulates circulating ghrelin during acute inflammation
Madison, L. D., Scarlett, J. M., Levasseur, P. R., Zhu, X., Newcomb, K. C., Batra, A. K., Bowe, D. D., & Marks, D. L. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0478 · Cited by 32 · cited 2×
“In a mouse model, PGI2 signaling decreased the level of circulating ghrelin, a peptide produced predominantly by the stomach, which has potent stimulatory effects on appetite [25].”
BackgroundEl-Haroun, H., Clarke, D. L., Deacon, K., Bradbury, D. A., Clayton, A., Sutcliffe, A., & Knox, A. J. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00044.2006 · Cited by 30
Gurgul-Convey, E., & Lenzen, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.054775 · Cited by 30 · cited 3×
“Cytokine toxicity is mediated in many cell types through the arachidonic acid metabolism pathway via inducible COX-2 production [3].”
BackgroundRegulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2analogues
Hung, C.-H., Chu, Y.-T., Suen, J., Lee, M., Chang, H.-W., Lo, Y.-C., & Jong, Y.-J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00070008 · Cited by 29 · cited 1×
“Iloprost increased IL-10 expression but inhibited toll-like receptor-mediated expression of TNF-α and IFN-α in human plasmacytoid dendritic cells suggesting an overall anti-inflammatory role [36].”
BackgroundThe roles of prostanoids in infection and sickness behaviors
Matsuoka, T., & Narumiya, S. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-008-0622-3 · Cited by 25 · cited 1×
“The cell surface receptor for PGI2 is a seven transmembrane G-protein-coupled receptor termed IP [6].”
BackgroundNovel Mechanism of the Vascular Protector Prostacyclin: Regulating MicroRNA Expression
Mohite, A. J., Chillar, A., So, S., Cervantes, V., & Ruan, K. (2011) · Biochemistry · doi:10.1021/bi101654w · Cited by 25 · cited 5×
“PPARs are responsive to not only PGI2 but also a broad range of ligands [15].”
BackgroundInfluentialBeraprost Enhances the APC Function of B Cells by Upregulating CD86 Expression Levels
Kim, J., Park, C.-S., Park, C. H., Jeoung, D., Kim, Y., & Choe, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002170 · Cited by 25 · cited 3×
“Increased T cell proliferation was noted after exposure to beraprost treated B cells [45] and suggests a role for beraprost as an adjuvant in vaccine development.”
BackgroundInfluentialZhou, W., Dowell, D. R., Geraci, M. W., Blackwell, T. S., Collins, R. D., Polosukhin, V. V., Lawson, W. E., Wu, P., Sussan, T. E., Biswal, S. S., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00224.2010 · Cited by 16 · cited 2×
“The PGIS-overexpressing mice had elevated levels of this antioxidant prior to administration of bleomycin and afterwards [30].”
BackgroundSelf-citationRevisiting prostacyclin: new directions in pulmonary fibrosis and inflammation
Soberman, R. J., & Christmas, P. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00102.2006 · Cited by 14 · cited 11×
“PGI2 has a long history of use for the treatment of pulmonary arterial hypertension (PAH) [14, 16, 28].”
BackgroundInfluentialWang, M., Cooper, P. R., Jiang, M., Zhao, H., Hui, Y., Yao, Y., Tate, J. C., Damera, G., Lawson, J. A., Jester, W. F., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166678 · Cited by 10 · cited 1×
“PGI2 regulates both the innate and adaptive immune systems and its effects are, for the most part, thought to be anti-inflammatory or immunosuppressive in nature, which may have implications for its further clinical use.”
BackgroundHashimoto, K., Ishibashi, K., Gebretsadik, T. S., Hartert, T. V., Yamamoto, A., Nakayama, T., Ohashi, K., Sakata, H., Kawasaki, Y., Katayose, M., et al. (2008) · Journal of Medical Virology · doi:10.1002/jmv.21318 · Cited by 8 · cited 2×
“Therefore, an association between lower numbers of PGIS VNTR repeats and increased severity of RSV infection identifies a host genetic factor associated with RSV disease severity [32].”
BackgroundSelf-citation
Cited by
Resolution of inflammation in bone regeneration: From understandings to therapeutic applications
Newman, H., Shih, Y. V., & Varghese, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121114 · Cited by 313
Proinflammatory Pathways: The Modulation by Flavonoids
Ribeiro, D., Freitas, M., Lima, J. L. F. C., & Fernandes, E. (2015) · Medicinal Research Reviews · doi:10.1002/med.21347 · Cited by 147
Metadata
- Authors
- Dorris, S. L., & Peebles, R. S.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-9
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2068594714
- Cited by
- 166
- References
- 44
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.